GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries: Presentation on Proposed USFDA Manufacturing Plant Acquisition

M&A ◆ Monitor Closely LOW RISK
📅 Filed on BSE: 14 Aug 2026, 12:46 PM IST  ·  BSE ID: 34d02c09-843c-409c-b7f8-e0bb6b5b4227
View Original BSE Filing (PDF)
💡
In Simple Terms
The company shared details about a manufacturing plant it plans to acquire, which makes drug ingredients and has international approvals.
🤖 AI Summary
  • Sudarshan Pharma Industries submitted a presentation on a proposed acquisition of a manufacturing plant.
  • The plant is a 14-acre facility, 40km from Visakhapatnam Airport, manufacturing API and API Intermediates.
  • The facility is approved by USFDA (ANDA-217608) in 2024, WHO Geneva in 2024, and ANVISA in 2025.
  • It does not produce steroids, penicillin, Beta lactam antibiotics, hormones, or cytotoxic products.
  • Infrastructural facilities are provided by APIIC, including water supply and effluent management.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Site area
14 acres
Distance from Visakhapatnam Airport
40km
USFDA approval year
2024
WHO Geneva approval year
2024
ANVISA approval year
2025
🏢 How This Affects the Company
📈
Business Impact
Acquiring a USFDA-approved plant could expand Sudarshan Pharma's manufacturing capabilities for Active Pharmaceutical Ingredients (API) and API Intermediates. This could enable access to regulated markets where such approvals are mandatory.
⚙️
Operational Impact
The acquisition would add a 14-acre manufacturing site located near Visakhapatnam, supported by APIIC for water and waste management. This integrates established production and quality control processes into the company's operations.
⚠️
Risk Impact
The proposed acquisition of a facility with existing USFDA, WHO, and ANVISA approvals reduces the regulatory risk associated with establishing new compliant manufacturing sites. Due diligence on the plant's operational history and compliance records remains relevant.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing, as it is an update on a proposed acquisition.
👤
Who Is Affected
Existing shareholders may see the company's manufacturing capacity and market access expand if the proposed acquisition is completed. The strategic direction is towards regulated pharma markets.
🔍
Management Signal
Management is signaling a strategic intent to expand manufacturing capabilities, specifically targeting facilities with international regulatory approvals to strengthen its API and API Intermediates business.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Filing on definitive agreement for the proposed acquisition.
Announcement of financial terms and funding for the acquisition.
Updates on regulatory approvals required for acquisition completion.
LOW RISK The filing provides information about a proposed acquisition without disclosing financial commitments or new liabilities.
💡 Investor Takeaway
Sudarshan Pharma Industries shared a presentation on a proposed USFDA-approved manufacturing plant acquisition. The 14-acre facility is approved by USFDA (ANDA-217608), WHO Geneva, and ANVISA, focusing on API and API Intermediates. This details a potential expansion of regulated manufacturing capabilities.
⚖️ Strengths & Concerns

✅ Positives

  • The proposed manufacturing unit holds approvals from USFDA (ANDA-217608) in 2024, WHO Geneva in 2024, and ANVISA in 2025.
  • The facility is supported by APIIC for infrastructure including water supply, common effluent treatment, and hazardous waste management.
📅 Company Track Record
No previous filings were found for Sudarshan Pharma Industries Ltd, indicating limited public track record information for historical analysis.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Sudarshan Pharma Industries proposing to acquire?
Sudarshan Pharma Industries is proposing to acquire a manufacturing plant located 40km from Visakhapatnam Airport, spread over 14 acres.
What type of products does the proposed acquired plant manufacture?
The proposed acquired plant is engaged in manufacturing API (Active Pharmaceutical Ingredients) and API Intermediates.
Which international regulatory approvals does the proposed plant hold?
The proposed plant is approved by USFDA (ANDA-217608) in 2024, WHO Geneva in 2024, and ANVISA in 2025.
What infrastructural support is available for the proposed plant?
APIIC provides infrastructural facilities for the proposed plant, including water supply, Common Effluent Treatment Plant, Hazardous Waste Management, and Marine Outfall.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.